Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Metastatic Gastric Cancer

Interventions

DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.

DRUG

Nivolumab Injection

Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.

Trial Locations (1)

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY